Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

Meletios A Dimopoulos; Giampaolo Merlini; Frank Bridoux; Nelson Leung; Joseph Mikhael; Simon J Harrison; Efstathios Kastritis; Laurent Garderet; Alessandro Gozzetti; Niels W C J van de Donk; Katja C Weisel; Ashraf Z Badros; Meral Beksac; Jens Hillengass; Mohamad Mohty; P Joy Ho; Ioannis Ntanasis-Stathopoulos; Maria-Victoria Mateos; Paul Richardson; Joan Blade; Philippe Moreau; Jesus San-Miguel; Nikhil Munshi; S Vincent Rajkumar; Brian G M Durie; Heinz Ludwig; Evangelos Terpos; International Myeloma Working Group

doi:10.1016/S1470-2045(23)00223-1

Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

Standard

Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. / Dimopoulos, Meletios A; Merlini, Giampaolo; Bridoux, Frank; Leung, Nelson; Mikhael, Joseph; Harrison, Simon J; Kastritis, Efstathios; Garderet, Laurent; Gozzetti, Alessandro; van de Donk, Niels W C J; Weisel, Katja C; Badros, Ashraf Z; Beksac, Meral; Hillengass, Jens; Mohty, Mohamad; Ho, P Joy; Ntanasis-Stathopoulos, Ioannis; Mateos, Maria-Victoria; Richardson, Paul; Blade, Joan; Moreau, Philippe; San-Miguel, Jesus; Munshi, Nikhil; Rajkumar, S Vincent; Durie, Brian G M; Ludwig, Heinz; Terpos, Evangelos; International Myeloma Working Group.

In: LANCET ONCOL, Vol. 24, No. 7, 07.2023, p. e293-e311.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Dimopoulos, MA, Merlini, G, Bridoux, F, Leung, N, Mikhael, J, Harrison, SJ, Kastritis, E, Garderet, L, Gozzetti, A, van de Donk, NWCJ, Weisel, KC, Badros, AZ, Beksac, M, Hillengass, J, Mohty, M, Ho, PJ, Ntanasis-Stathopoulos, I, Mateos, M-V, Richardson, P, Blade, J, Moreau, P, San-Miguel, J, Munshi, N, Rajkumar, SV, Durie, BGM, Ludwig, H, Terpos, E & International Myeloma Working Group 2023, 'Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group', LANCET ONCOL, vol. 24, no. 7, pp. e293-e311. https://doi.org/10.1016/S1470-2045(23)00223-1

APA

Dimopoulos, M. A., Merlini, G., Bridoux, F., Leung, N., Mikhael, J., Harrison, S. J., Kastritis, E., Garderet, L., Gozzetti, A., van de Donk, N. W. C. J., Weisel, K. C., Badros, A. Z., Beksac, M., Hillengass, J., Mohty, M., Ho, P. J., Ntanasis-Stathopoulos, I., Mateos, M-V., Richardson, P., ... International Myeloma Working Group (2023). Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. LANCET ONCOL, 24(7), e293-e311. https://doi.org/10.1016/S1470-2045(23)00223-1

Vancouver

Dimopoulos MA, Merlini G, Bridoux F, Leung N, Mikhael J, Harrison SJ et al. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. LANCET ONCOL. 2023 Jul;24(7):e293-e311. https://doi.org/10.1016/S1470-2045(23)00223-1

Bibtex

@article{cd145a6becb04dbf9caee9e955a78c80,

title = "Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group",

abstract = "Here, the International Myeloma Working Group (IMWG) updates its clinical practice recommendations for the management of multiple myeloma-related renal impairment on the basis of data published until Dec 31, 2022. All patients with multiple myeloma and renal impairment should have serum creatinine, estimated glomerular filtration rate, and free light chains (FLCs) measurements together with 24-h urine total protein, electrophoresis, and immunofixation. If non-selective proteinuria (mainly albuminuria) or involved serum FLCs value less than 500 mg/L is detected, then a renal biopsy is needed. The IMWG criteria for the definition of renal response should be used. Supportive care and high-dose dexamethasone are required for all patients with myeloma-induced renal impairment. Mechanical approaches do not increase overall survival. Bortezomib-based regimens are the cornerstone of the management of patients with multiple myeloma and renal impairment at diagnosis. New quadruplet and triplet combinations, including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies, improve renal and survival outcomes in both newly diagnosed patients and those with relapsed or refractory disease. Conjugated antibodies, chimeric antigen receptor T-cells, and T-cell engagers are well tolerated and effective in patients with moderate renal impairment.",

keywords = "Humans, Multiple Myeloma/complications, Dexamethasone, Antineoplastic Agents/adverse effects, Renal Insufficiency/etiology, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Bortezomib/therapeutic use",

author = "Dimopoulos, {Meletios A} and Giampaolo Merlini and Frank Bridoux and Nelson Leung and Joseph Mikhael and Harrison, {Simon J} and Efstathios Kastritis and Laurent Garderet and Alessandro Gozzetti and {van de Donk}, {Niels W C J} and Weisel, {Katja C} and Badros, {Ashraf Z} and Meral Beksac and Jens Hillengass and Mohamad Mohty and Ho, {P Joy} and Ioannis Ntanasis-Stathopoulos and Maria-Victoria Mateos and Paul Richardson and Joan Blade and Philippe Moreau and Jesus San-Miguel and Nikhil Munshi and Rajkumar, {S Vincent} and Durie, {Brian G M} and Heinz Ludwig and Evangelos Terpos and {International Myeloma Working Group}",

year = "2023",

month = jul,

doi = "10.1016/S1470-2045(23)00223-1",

language = "English",

volume = "24",

pages = "e293--e311",

journal = "LANCET ONCOL",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "7",

}

RIS

TY - JOUR

T1 - Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

AU - Dimopoulos, Meletios A

AU - Merlini, Giampaolo

AU - Bridoux, Frank

AU - Leung, Nelson

AU - Mikhael, Joseph

AU - Harrison, Simon J

AU - Kastritis, Efstathios

AU - Garderet, Laurent

AU - Gozzetti, Alessandro

AU - van de Donk, Niels W C J

AU - Weisel, Katja C

AU - Badros, Ashraf Z

AU - Beksac, Meral

AU - Hillengass, Jens

AU - Mohty, Mohamad

AU - Ho, P Joy

AU - Ntanasis-Stathopoulos, Ioannis

AU - Mateos, Maria-Victoria

AU - Richardson, Paul

AU - Blade, Joan

AU - Moreau, Philippe

AU - San-Miguel, Jesus

AU - Munshi, Nikhil

AU - Rajkumar, S Vincent

AU - Durie, Brian G M

AU - Ludwig, Heinz

AU - Terpos, Evangelos

AU - International Myeloma Working Group

PY - 2023/7

Y1 - 2023/7

N2 - Here, the International Myeloma Working Group (IMWG) updates its clinical practice recommendations for the management of multiple myeloma-related renal impairment on the basis of data published until Dec 31, 2022. All patients with multiple myeloma and renal impairment should have serum creatinine, estimated glomerular filtration rate, and free light chains (FLCs) measurements together with 24-h urine total protein, electrophoresis, and immunofixation. If non-selective proteinuria (mainly albuminuria) or involved serum FLCs value less than 500 mg/L is detected, then a renal biopsy is needed. The IMWG criteria for the definition of renal response should be used. Supportive care and high-dose dexamethasone are required for all patients with myeloma-induced renal impairment. Mechanical approaches do not increase overall survival. Bortezomib-based regimens are the cornerstone of the management of patients with multiple myeloma and renal impairment at diagnosis. New quadruplet and triplet combinations, including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies, improve renal and survival outcomes in both newly diagnosed patients and those with relapsed or refractory disease. Conjugated antibodies, chimeric antigen receptor T-cells, and T-cell engagers are well tolerated and effective in patients with moderate renal impairment.

AB - Here, the International Myeloma Working Group (IMWG) updates its clinical practice recommendations for the management of multiple myeloma-related renal impairment on the basis of data published until Dec 31, 2022. All patients with multiple myeloma and renal impairment should have serum creatinine, estimated glomerular filtration rate, and free light chains (FLCs) measurements together with 24-h urine total protein, electrophoresis, and immunofixation. If non-selective proteinuria (mainly albuminuria) or involved serum FLCs value less than 500 mg/L is detected, then a renal biopsy is needed. The IMWG criteria for the definition of renal response should be used. Supportive care and high-dose dexamethasone are required for all patients with myeloma-induced renal impairment. Mechanical approaches do not increase overall survival. Bortezomib-based regimens are the cornerstone of the management of patients with multiple myeloma and renal impairment at diagnosis. New quadruplet and triplet combinations, including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies, improve renal and survival outcomes in both newly diagnosed patients and those with relapsed or refractory disease. Conjugated antibodies, chimeric antigen receptor T-cells, and T-cell engagers are well tolerated and effective in patients with moderate renal impairment.

KW - Humans

KW - Multiple Myeloma/complications

KW - Dexamethasone

KW - Antineoplastic Agents/adverse effects

KW - Renal Insufficiency/etiology

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects

KW - Bortezomib/therapeutic use

U2 - 10.1016/S1470-2045(23)00223-1

DO - 10.1016/S1470-2045(23)00223-1

M3 - SCORING: Review article

C2 - 37414019

VL - 24

SP - e293-e311

JO - LANCET ONCOL

JF - LANCET ONCOL

SN - 1470-2045

IS - 7

ER -